Lankenau Institute for Medical Research, the biomedical research center for Main Line Health, received a $3.1 million, five-year grant award from the National Cancer Institute (NCI) to conduct clinical trials of new oncology drugs and perform additional research to improve patient care.
This award for an NCI Community Oncology Research Program (NCORP) supports all NCI-sponsored clinical trials, which is conducted by Main Line Health oncologists, relates to cancer prevention, screening, treatment and post-treatment management. NCORP also supports research into cancer care delivery, which focuses on improving health and quality of life outcomes, identifying and addressing any disparities of care among individual patients, and gaining a more integrated understanding of all the costs involved in effective health management.
Main Line Health is one of only 34 health care organizations in the U.S. to receive an NCORP award from NCI, testifying to the national strengths of the Main Line Health hospitals in delivering and continuously improving cancer care. NCORP supports oncology research at all Main Line Health hospitals, including Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital.
The Principal Investigator for the Main Line Health NCORP award is Albert DeNittis, MD, Chief of Radiation Oncology at Lankenau Medical Center, with Associate Principal Investigator John Devlin, MD, Bryn Mawr Hospital; site investigators Michael Dabrow, DO, at Paoli Hospital; and Rashmi Sanjay, MD, at Riddle Hospital.
“Having the NCORP available at all four acute care hospitals in the system expands the access our patients have to innovative treatment care options and highlights another way we strive to provide a superior patient experience to each Main Line Health patient,” said Diana Blade, Administrator of Cancer Clinical Trials at Lankenau Institute for Medical Research. “Our relationship with the NCI allows us to contribute in a meaningful way to cancer research and treatments that lead to medical breakthroughs.”
Founded in 1985, Main Line Health (MLH) is a not-for-profit health system serving portions of Philadelphia and its western suburbs. At its core are four of the region’s respected acute care hospitals — Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital — as well as one of the nation’s premier facilities for rehabilitative medicine, Bryn Mawr Rehab Hospital; Mirmont Treatment Center for drug and alcohol recovery; and the Home Care Network, a home health service. Main Line Health also consists of Main Line HealthCare, one of the region’s largest multi-specialty physician networks, and the Lankenau Institute for Medical Research, a non-profit biomedical research organization located on the campus of Lankenau Medical Center. Main Line Health also consists of four outpatient health centers located in Broomall, Collegeville, Exton and Newtown Square. Main Line Health hospitals, with more than 10,000 employees and 2,000 physicians, are the recipients of numerous awards for quality care and service, including recognition among Truven Health Analytics’ list of Top 100 Hospitals and top 20% of health systems in the nation, and Magnet®, the nation’s highest honor for nursing excellence. Main Line Health is among the area’s leaders in medicine, providing advanced patient-centered care, education and research to help our community stay healthy.
Mary Kate Coghlan
© 2014 Main Line Health